ASP-1929 not checked
Rakuten Medical, Inc. · PIT690 Laser System
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)”In the company’s words, NCT06699212 on ClinicalTrials.gov
- Tested for
- Recurrent Head and Neck Squamous Cell Carcinoma (2 trials), Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
- Main trialPhase 3
- “A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy”In the company’s words, NCT03769506 on ClinicalTrials.gov
- Other names
- cetuximab sarotalocan · PIT690 Laser System
Other drugs for Recurrent Head and Neck Squamous Cell Carcinoma
- APG-157Aveta Biomics, Inc. · Phase 3
- PembrolizumabMerck & Co. · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- FiclatuzumabAVEO Pharmaceuticals, Inc. · Phase 3
- SYS6002CSPC · Phase 3
- MRG003Lepu Biopharma Co., Ltd. · Phase 3
Coming up1
- Sep 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2025 | ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | |
| Phase 3Recruiting | Sep 2028 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases | |
| Phase 1/2Active, not recruiting | Jun 2026 | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | |
| Phase 2Terminated | 20 Nov 2023 | ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases | |
| Phase 2Unknown | 11 Jul 2024 | ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026